SMMT NASDAQ
Summit Therapeutics Inc.
1W: -16.4%
1M: -36.9%
3M: -0.2%
YTD: -9.5%
1Y: -33.6%
3Y: +821.5%
5Y: +189.8%
$17.89
+2.04 (+12.87%)
After Hours: $17.29 (-0.60, -3.35%)
Weekly Expected Move ±15.5%
$12
$14
$17
$19
$22
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$12.3B
52W Range13.83-30.98
Volume2,642,513
Avg Volume3,419,816
Beta-1.25
Dividend—
Analyst Ratings
Company Info
CEORobert W. Duggan
Employees159
SectorHealthcare
IndustryBiotechnology
IPO Date2015-03-05
Websitesummittxinc.com
One Broadway
Cambridge, MA 02142
US
Cambridge, MA 02142
US
617 514 7149
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Latest News
Cancer Stocks That Are Advancing the Future of Oncology Care
H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT)
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Anand Bhaskar | A-Award | 30,000 | $18.83 | 2026-01-08 |
| Zanganeh Mahkam | A-Award | 11,232 | $17.52 | 2026-01-02 |
| DUGGAN ROBERT W | A-Award | 11,232 | $17.52 | 2026-01-02 |
| Booth Robert F. | A-Award | 35,000 | $17.52 | 2026-01-02 |
| Booth Robert F. | A-Award | 7,180 | $17.52 | 2026-01-02 |